Canaccord Genuity Downgrades Ventyx Biosciences to Hold, Lowers Price Target to $14

Benzinga · 2d ago
Canaccord Genuity analyst Edward Nash downgrades Ventyx Biosciences (NASDAQ:VTYX) from Buy to Hold and lowers the price target from $16 to $14.